The randomized, double-blind, placebo-controlled study assesses the safety, tolerability, and pharmacokinetics of XYL-1001 in healthy volunteers. By utilizing both single and multiple ascending dose cohorts, the company aims to establish a pharmacological foundation for the drug. Xylo Bio is presenting the program this week at the 9th Neuropsychiatric Drug Development Summit in Boston.

XYL-1001 is engineered to activate the 5-HT2A receptor while avoiding the hallucinogenic effects common to other psychedelic-based treatments. According to Chief Scientific Officer Dr. Samuel Banister, the goal is to unlock therapeutic neuroplasticity without the intensive medical supervision required by current psychedelic therapies. Preclinical models have shown the compound effectively addresses anxiety and depressive-like behaviors without the hallmark signs of hallucinogenic activity. This development seeks to bridge the treatment gap for the estimated 332 million people worldwide suffering from depression, particularly the one-third of patients who fail to respond to traditional antidepressants.